Viral syncytia evolve to resist interferon.
Summary
This mechanistic study demonstrates that spike-driven syncytia blunt interferon antiviral activity and reduce antibody neutralization across systems, including human lung cultures and hACE2 mice. Mutations that enhance syncytia formation in SARS-CoV-2 parallel increases in interferon resistance, and FAST protein-driven syncytia confer similar advantages across multiple respiratory viruses.
Key Findings
- Spike-mediated syncytia reduced interferon antiviral effects in cultured cells, human lung cell cultures, and hACE2 mice.
- Mutations modulating syncytia in Delta/Omicron also modulated interferon resistance.
- Syncytia formation compromised antibody-mediated neutralization in vitro.
- FAST protein-induced syncytia recapitulated interferon and antibody resistance in VSV, influenza, and OC43.
Clinical Implications
Therapeutic strategies may need to target cell–cell fusion or downstream pathways to restore interferon efficacy and neutralization; surveillance should monitor fusogenicity as a correlates of immune escape and transmission.
Why It Matters
It reveals a unifying mechanism of innate and adaptive immune escape via syncytia, explaining selection of highly fusogenic SARS-CoV-2 variants and generalizing to other respiratory viruses.
Limitations
- Mechanistic study without human clinical outcomes
- Quantitative in vivo correlates of transmission and disease severity were not assessed
Future Directions
Define molecular targets to inhibit fusion-mediated immune escape, and develop assays to monitor fusogenicity in clinical isolates to inform variant risk and antiviral design.
Study Information
- Study Type
- Basic/Mechanistic Research
- Research Domain
- Pathophysiology
- Evidence Level
- V - Preclinical mechanistic experiments across in vitro systems and animal models
- Study Design
- OTHER